Targeting the G2/M Checkpoint in Glioblastoma with a Combined Loss of TP53 and CDKN2A

Abstract

This study aims to evaluate the effectiveness of G2/M checkpoint inhibitors as single therapeutic agent, or in combination with radiotherapy, a current standard therapy in GBM, as well as aims to identify new biomarkers for CHK1/2 sensitive GBMs. Successful completion of the aims will help us examine the effects of anew therapeutic strategy against GBM in specific molecular context.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Nov 01, 2021
Accession Number
AD1165690

Entities

People

  • Sangita Pal

Organizations

  • Dana–Farber Cancer Institute

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biological Factors
  • Biological Markers
  • Biomedical Research
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Data Analysis
  • Department Of Defense
  • Genes
  • Genetic Structures
  • Genetics
  • Genome
  • Health Services
  • Indirect Costs
  • Inhibitors
  • Lethality
  • Medical Personnel
  • Neoplasms
  • Standards
  • Stem Cells
  • Therapy
  • United States

Fields of Study

  • Biology
  • Chemistry

Readers

  • Mathematics or Statistics
  • Oncology